USE OF RENIN-ANGIOTENSIN ANTAGONIST FOR REDUCING POST MYOCARDIAL INFARCT MORTALITY

The invention involves a method for treating a human survivor of a heart attack and provides further improvement in survival following the heart attack by the early initiation and long-term administration of a renin-angiotensin system inhibitor, preferably an angiotensin converting enzyme inhibitor. The inhibitor may be used on its own, or in conjunction with other therapeutic compounds such as β blockers and thrombolytic agents. The preferred inhibitor is captopril.
## FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>AT</td>
<td>Austria</td>
<td>FR</td>
<td>France</td>
<td>MR</td>
<td>Mauritania</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AU</td>
<td>Australia</td>
<td>GA</td>
<td>Gabon</td>
<td>MW</td>
<td>Malawi</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BB</td>
<td>Barbados</td>
<td>GB</td>
<td>United Kingdom</td>
<td>NL</td>
<td>Netherlands</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BE</td>
<td>Belgium</td>
<td>GN</td>
<td>Guinea</td>
<td>NO</td>
<td>Norway</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BF</td>
<td>Burkina Faso</td>
<td>GR</td>
<td>Greece</td>
<td>NZ</td>
<td>New Zealand</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BG</td>
<td>Bulgaria</td>
<td>HU</td>
<td>Hungary</td>
<td>PL</td>
<td>Poland</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BJ</td>
<td>Benin</td>
<td>IE</td>
<td>Ireland</td>
<td>PT</td>
<td>Portugal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BR</td>
<td>Brazil</td>
<td>IT</td>
<td>Italy</td>
<td>RO</td>
<td>Romania</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CA</td>
<td>Canada</td>
<td>JP</td>
<td>Japan</td>
<td>RU</td>
<td>Russian Federation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CF</td>
<td>Central African Republic</td>
<td>KP</td>
<td>Democratic People's Republic of Korea</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CG</td>
<td>Congo</td>
<td></td>
<td></td>
<td>SD</td>
<td>Sudan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CH</td>
<td>Switzerland</td>
<td>KR</td>
<td>Republic of Korea</td>
<td>SE</td>
<td>Sweden</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CI</td>
<td>Côte d'Ivoire</td>
<td>KZ</td>
<td>Kazakhstan</td>
<td>SK</td>
<td>Slovak Republic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CM</td>
<td>Cameroon</td>
<td>LI</td>
<td>Liechtenstein</td>
<td>SN</td>
<td>Senegal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CS</td>
<td>Czechoslovakia</td>
<td>LK</td>
<td>Sri Lanka</td>
<td>SU</td>
<td>Soviet Union</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CZ</td>
<td>Czech Republic</td>
<td>LU</td>
<td>Luxembourg</td>
<td>TD</td>
<td>Chad</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DE</td>
<td>Germany</td>
<td>MC</td>
<td>Monaco</td>
<td>TG</td>
<td>Togo</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DK</td>
<td>Denmark</td>
<td>MG</td>
<td>Madagascar</td>
<td>UA</td>
<td>Ukraine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ES</td>
<td>Spain</td>
<td>ML</td>
<td>Mali</td>
<td>US</td>
<td>United States of America</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FI</td>
<td>Finland</td>
<td>MN</td>
<td>Mongolia</td>
<td>VN</td>
<td>Viet Nam</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
USE OF RENIN-ANGIOTENSIN ANTAGONIST FOR REDUCING POST MYOCARDIAL INFARCT MOBILITY AND MORTALITY

Survivors of acute myocardial infarction are at greatly increased risk for subsequent fatal and non-fatal cardiovascular events (1). This heightened risk is not a uniform one, but rather is influenced by many factors such as age, co-morbid diseases, extent of coronary artery disease, electrical stability, and, most importantly, the severity of left ventricular dysfunction. Irrespective of how the latter is measured (ventricular volumes, ejection fraction, contraction score), the severity of dysfunction correlates highly with mortality and thus is useful in stratifying survivors of acute myocardial infarction into categories of varying risk (2,3,4,5). Of these indices of left ventricular impairment, the most powerful predictor of survival is ventricular volume (4,5).

In a rat model of myocardial infarction produced by ligation of the left coronary artery, progressive left ventricular dilation has been shown to occur as a
function of the size and age of the infarct (6,7). During the acute post-infarction phase, prior to scar formation, an increase in ventricular diastolic volume occurs as a consequence of infarct expansion and a rise in filling pressure (8,9). Following formation of a discrete scar, left ventricular dilation may continue as the result of a remodeling of the residual viable myocardium, initially acting to restore stroke volume (9,10). If the infarct is of sufficient size, the increase in diastolic volume may progress, leading to further deterioration in ventricular performance and perpetuation of the dilatation (11). In a rat model of myocardial infarction, the chronic administration of the angiotensin converting enzyme inhibitor, captopril, has been shown to attenuate this gradual dilatation of the left ventricle both by remodeling its structure and reducing its distending pressure, leading to an improvement in cardiac function (12) and, in long-term studies, a prolongation of survival (12,13).

Although this animal data is encouraging, it is by no means predictive of what will happen in humans. In fact, the NIH has been critical of pre-clinical data based upon rat models (personal communication), and a recent clinical trial based upon rat data of improved survival with therapy using an angiotensin converting enzyme inhibitor (milirone) resulted in an opposite conclusion (excess death) in humans (14). In still another study, an angiotensin converting enzyme inhibitor (cilazapril) was ineffective in preventing
restenosis following coronary angioplasty in humans, despite the efficacy of cilazapril in preventing restenosis in a rat model (15). We believe further that it is impossible to extrapolate from rat studies to humans in connection with coronary artery disease because rats do not actually have coronary artery disease. They also do not have the associated medical problems following human myocardial infarction that require concomitant therapies, further confounding any attempted extrapolation.

Recently, several clinical studies have confirmed the progressive nature of left ventricular enlargement and dysfunction in patients during the late phase following a myocardial infarction (10,16). So too has chronic therapy with angiotensin converting enzyme inhibition been shown to attenuate ventricular enlargement and prevent a further deterioration of performance in this patient population (17, 18). Although the endpoints in these studies, e.g., ventricular size and function, were well-defined, the sample sizes were too small to address the critical clinical issue, i.e., the influence of angiotensin converting enzyme inhibitor therapy on long-term survival and clinical outcome.

One recent study, initiated after ours, set out to test whether treatment for six months with an angiotensin converting enzyme inhibitor (enalapril) might have a beneficial effect on mortality in patients who have had myocardial infarction. That study concluded that there was no beneficial effect on
mortality. In fact, the study was terminated "because of a recommendation of the safety committee" (19).

It is an object of the invention to provide a method for increasing the chances of survival in humans who have had a heart attack.

Another object of the invention is to provide a method for lessening deterioration in cardiac performance and improving clinical outcome in human survivors of a heart attack.

Accordingly and in a first aspect the present invention provides the use of a renin-angiotensin system inhibitor for the manufacture of a medicament for use in a method of treating a human survivor of a heart attack by long-term administration of said medicament.

In a second aspect the present invention provides the use of a renin-angiotensin system inhibitor for the manufacture of a medicament for use in a method of treating a human survivor of a heart attack, wherein the human survivor is free of indications for renin-angiotensin system inhibitor treatment.

Preferably, in a further aspect the present invention provides a composition comprising a renin-angiotensin system inhibitor in admixture with a further compound or composition which is therapeutically active in the treatment of heart attack consequences but which is not a renin-angiotensin system inhibitor.
Preferably, the renin-angiotensin system inhibitor is a renin inhibitor, an angiotensin converting enzyme inhibitor or an angiotensin II antagonist. At least in the case of angiotensin converting enzyme inhibitor, it is preferred that the administration be early and long-term. It is desirable, however, to begin such treatment only after three days have elapsed from the date of the heart attack, and it further is desirable to gradually increase the dose. Most preferably, the angiotensin converting enzyme inhibitor is captopril.

The renin-angiotensin system inhibitor may be used alone or in conjunction with other compounds that are known to reduce adverse health consequences that occur following a heart attack. For example, the beneficial results of treatment with captopril are present when captopril is administered in conjunction with either beta-adrenergic blocking agents, aspirin or thrombolytic agents.

Preferred embodiments of the various aspects of the invention are defined and described in the sub-claims appended hereto.

These and other aspects of the invention will be described in greater detail below.

**BRIEF DESCRIPTION OF THE DRAWINGS**

Fig. 1 is a graph depicting all cause mortality for placebo treated survivors compared to captopril treated survivors.

Fig. 2 is a bar graph depicting adverse health
consequences for placebo treated survivors compared to captopril treated survivors.

Fig. 3 is a graph depicting cardiovascular mortality for placebo treated survivors compared to captopril treated survivors.

Fig. 4 is a graph depicting congestive heart failure (requiring angiotensin converting enzyme inhibition treatment) for placebo treated survivors compared to captopril treated survivors.

Fig. 5 is a graph depicting congestive heart failure (requiring hospitalization) for placebo treated survivors compared to captopril treated survivors.

Fig. 6 is a graph depicting recurrent myocardial infarction for placebo treated survivors compared to captopril treated survivors.

Fig. 7 is a graph depicting cardiovascular mortality plus recurrent myocardial infarction for placebo treated survivors compared to captopril treated survivors.

Fig. 8 is a graph depicting cardiovascular mortality plus morbidity for placebo treated survivors compared to captopril treated survivors.

The present invention is useful in the treatment of heart attack survivors. Such treatment involves therapy with a renin-angiotensin system inhibitor, preferably an angiotensin converting enzyme inhibitor, in survivors with depressed left ventricular ejection fraction but without overt heart failure, and it can
result in reductions in total and cardiovascular mortality, in the frequency of development of severe congestive heart failure and of recurrent myocardial infarction, and in the proportion of patients who either died or survived with a marked deterioration in left ventricular ejection fraction.

The renin-angiotensin system is involved in the regulation of hemodynamics and water and electrolyte balance. Factors that lower blood volume, renal perfusion pressure, or the concentration of Na⁺ in plasma tend to activate the system, while factors that increase these parameters tend to suppress its function.

An overview of the pathway for synthesis of the angiotensins in vivo is as follows. The process is initiated when the enzyme renin acts on angiotensinogen, a pseudoglobulin in blood plasma, to produce the decapeptide angiotensin I. Angiotensin I is converted by angiotensin converting enzyme (ACE) to angiotensin II (angiotensin-[1-8] octapeptide). The latter is an active pressor substance which has been implicated as the causative agent in several forms of hypertension in various mammalian species, e.g., humans.

Renin-angiotensin system inhibitors as defined herein are compounds that act to interfere with the production of angiotensin II from angiotensinogen or to interfere with the activity of angiotensin II. Such inhibitors are well known to those of ordinary skill in the art and include compounds that act to
inhibit the enzymes involved in the production of angiotensin II, including renin and ACE. They also include compounds that act on the substrates of these enzymes and compounds that interfere with the activity of angiotensin II, once produced. Examples of classes of such compounds include antibodies (e.g. to renin or to ACE), amino acids and analogs thereof (including those conjugated to larger molecules), peptides (including peptide analogs of angiotensinogen and angiotensin I), pro-renin related analogs, phospholipids and more. Among the most potent and useful renin-angiotensin system inhibitors are renin inhibitors, ACE inhibitors and angiotensin II antagonists.

Renin inhibitors are well known and include amino acids and derivates thereof, peptides and derivatives thereof and antibodies to renin. Examples of renin inhibitors that are the subject of United States patents are as follows: urea derivatives of peptides (U.S. 5,116,835); amino acids connected by nonpeptide bonds (U.S. 5114,937); di- and tripeptide derivatives (U.S. 5,106,835); amino acids and derivatives thereof (U.S. 5,104,869 and 5,095,119); diol sulfonamides and sulfinyls (U.S. 5,098,924); modified peptides (U.S. 5,095,006); peptidyl beta-aminoacyl aminodiol carbamates (U.S. 5,089,471); pyrolimidazolones (U.S. 5,075,451); fluorine and chlorine statine or statone containing peptides (U.S. 5,066,643); peptidyl amino diols (U.S. 5,063,208 and U.S. 4,845,079); N-morpholino derivatives (U.S.

ACE inhibitors intervene in the angiotensin (renin) angiotensin I angiotensin II sequence by inhibiting angiotensin converting enzyme and reducing or eliminating the formation of the pressor substance angiotensin II. ACE inhibitors are useful as antihypertensive agents and for treating congestive heart failure.

ACE inhibitors are well known and include amino acids and derivatives thereof, peptides including di- and tri-peptides and antibodies to ACE. Classes of compounds known to be useful as ACE inhibitors include acylmercapto and mercaptoalkanoyl prolines such as captopril (U.S. Patent 4,105,776) and zofenopril (U.S. Patent 4,316,906), carboxyalkyl dipeptides such as enalapril (U.S. Patent 4,374,829), lisinopril (Id.), quinapril (U.S. Patent 4,344,949), ramipril (U.S. Patent 4,587,258), and perindopril (U.S. Patent 4,508,729), carboxyalkyl dipeptide mimics such as cilazapril (U.S. Patent 4,512,924) and benazepril (U.S. Patent 4,410,520), phosphinylalkanoyl prolines such as fosinopril (U.S. Patent 4,337,201) and trandolopril.

Angiotensin II inhibitors are compounds that interfere with the activity of angiotensin II.
Angiotensin II inhibitors include angiotensin II antagonists and antibodies to angiotensin II. Preferred are the AT$_1$ specific antagonists. Angiotensin II antagonists are well known and include peptide compounds and nonpeptide compounds. Most angiotensin II antagonists are slightly modified congeners in which agonist activity is attenuated by replacement of phenylalanine in position 8 with some other amino acid; stability can be enhanced by other replacements that slow degeneration in vivo. Examples of angiotensin II antagonists include: peptidic compounds (e.g. saralasin, [San$^1$, Val$^5$, Ala$^8$] angiotensin -(1-8) octapeptide and related analogs); N-substituted imidazole-2-one (U.S. 5,087,634); imidazole acetate derivatives including 2-n-butyl-4-chloro-1-(2-chlorobenzyl) imidazole-5-acetic acid (see Wong et al., J. Pharmacol. Exp. Ther. 247 (1), 1-7 (1988)); 4, 5, 6, 7-tetrahydro-1 H-imidazo [4,5-c] pyridine-6-carboxylic acid and analogs derivatives (U.S. 4,816,463); N 2-tetrazole beta-glucuronide analogs (U.S. 5,085,992); substituted pyroles, pyrazoles and triazoles (U.S. 5,081,127); phenyl and heterocyclic derivatives such as 1, 3-imidazoles (U.S. 5,073,566); imidazo-fused 7-member ring heterocycles (U.S. 5,064,825); peptides (e.g. U.S. 4,772,684); antibodies to angiotensin II (e.g. U.S. 4,302,386); and aralkyl imidazole compounds such as biphenyl-methyl substituted imidazoles (e.g. EP no. 253,310, January 20, 1988). Other angiotensin II inhibitors currently being tested include ES-8891
(N-morpholinoacetyl-(1-naphthyl)-L-alanyl-(4-thiazolyl)-L-alanyl(35, 45)-4-amino-3-hydroxy-5-cyclo-hexapenta-
noyl-n-hexylamide, Sankyo Company Ltd., Tokyo, Japan),
SK&F 108566 (E-α-2-[2-butyl-1-[(carboxyphenyl)
methyl] 1H-imidazol-5-yl]methylene]-2-
thiophenepropanoic acid, SmithKline Beecham
Pharmaceuticals, PA), Losartan (DUP 753/MK 954, DuPont
Merck Pharmaceutical Co.), Remikirin (RO 42-5892, F.
Hoffmann LaRoche AG), Adenosine A2 agonists (Marion
Merrell Dow) and certain nonpeptide heterocycles (G.D.
Searle & Company).

(The disclosures of the foregoing patents
relating to renin inhibitors, ACE inhibitors and
angiotensin II inhibitors are incorporated herein by
reference.)

The foregoing compounds never before have been
given early and for extended periods of time to heart
attack survivors who are otherwise free of indications
for renin-angiotensin system inhibitors. By "free of
indications for renin-angiotensin system inhibitor
treatment", it is meant that the survivor does not
have symptoms or a clinical history that call for
treatment with an a renin-angiotensin system inhibitor
(other than the indication which exists as a result of
this invention). In other words, treatment is given
to survivors who do not exhibit, among other things,
symptomatic congestive heart failure, or systemic
hypertension, or specifically in the case of a renin
inhibitor, hyperaldosterism, glaucoma, diabetic
nephropathy and certain diseases caused by retrovirus
including HTLV-I, II and III. By "long-term" or "extended period" it is meant greater than usual in an acute drug treatment of disease and, preferably, greater than six months. Preferably, the renin-angiotensin system inhibitor is administered continuously and substantially without interruption for at least two years.

In the preferred embodiment, an ACE inhibitor is employed, and the ACE inhibitor is not administered to the survivor immediately following the heart attack. Instead, the start of medication is delayed for several days, preferably three. In addition, it is preferred that the survivor first receive a relatively low dose of the ACE inhibitor, gradually increasing that dose to the maximum tolerable dose. By "maximum" dose, it is meant the highest dose that is free of medically unacceptable side effects, i.e., the highest safe dose according to sound medical judgment. By "tolerable" dose, it is meant the highest dose that a patient is willing to take. It thus will be understood by those of ordinary skill in the art that although the maximum dose may be preferred, any particular survivor may insist on a lower dose for medical reasons, for psychological reasons or for virtually any other reason.

In the most preferred embodiment, the ACE inhibitor is a tablet containing captopril (U.S. Patent 4,105,776, sold by Bristol-Myers Squibb). The captopril is administered orally in tablet form, beginning three days after the heart attack (and
preferably not later than sixteen days after the heart attack). It is administered first at a dose of less than 20 mg per day, and gradually increased to the maximum dose of 150 mg per day. Preferably the captopril is administered three times per day to achieve these doses.

Somewhat surprisingly, the renin-angiotensin system inhibitor still achieves a beneficial effect when co-administered with non-system inhibitor compounds that reduce the risk of adverse health consequences occurring after a heart attack. For example, aspirin, beta-adrenergic blocking agents, anticoagulants and thrombolytic agents are known to produce beneficial effects when administered to heart attack survivors. When the ACE inhibitors are co-administered with such compounds, the effect is cumulative; that is, the beneficial effects of the invention are present over and above the beneficial effects of the other compounds.

The renin-angiotensin system inhibitor may be administered by any medically-acceptable route, including oral, rectal, topical, nasal, transcutaneous or parenteral (e.g., subcutaneous, intermuscular and intravenous) routes. The preferred route is oral. Formulations of the inhibitor suitable for oral administration include discrete units such as capsules, tablets, lozenges and the like. The preferred formulation is a tablet.

In the methods to which the invention relates, the renin-angiotensin system inhibitors are
administered in therapeutically effective amounts. Preferably, a "therapeutically effective amount" is that amount necessary to achieve a reduction in the risk of adverse health consequences. Adverse health consequences include congestive heart failure, recurrent myocardial infarction and/or death. The effective amount will vary according to the particular ACE inhibitor used and the mode of administration. It also may vary according to individual patient parameters including age, physical condition, size and weight. These factors are well-known to those of ordinary skill in the art and can be suitably addressed with no more than routine experimentation.

Typically, the dose range is from 1-1000 mg/kg body weight per day. Generally, treatment is initiated with dosages that are less than the optimum dose. Thereafter the dose is increased. The total daily dose can be administered in portions during the day, if desired.

As will be demonstrated in the example to follow, the early initiation and continued administration of an ACE inhibitor, captopril, to patients with asymptomatic left ventricular dysfunction following an acute myocardial infarction improved long-term overall survival and reduced the mortality and morbidity due to major cardiovascular events. In particular, overall deaths were reduced; congestive heart failure requiring ACE inhibitor treatment was reduced; and congestive heart failure requiring hospitalization was reduced. Additionally,
of the patients who developed congestive heart failure, survival was improved for those who had been receiving the ACE inhibitor prior to developing the symptoms of congestive heart failure.

**EXAMPLE**

**Study Organization**

The trial was a randomized, double-blind, placebo-controlled trial of 2231 patients with an acute myocardial infarction and left ventricular dysfunction who were enrolled at 45 clinical centers.

**Patient Recruitment**

The enrollment phase of the trial began on January 27, 1987 and ended on January 28, 1990. To be considered for recruitment, patients of either gender had to survive the first three days of a myocardial infarction with a radionuclide left ventricular ejection fraction < 40 percent and be at least 21 but under 80 years of age. A myocardial infarction was considered to have occurred if the patient experienced either (1) acute changes in an electrocardiogram (Q or QS finding plus ST elevation and/or T-Wave inversion plus absence of left bundle branch block or Wolff-Parkinson-White syndrome) obtained shortly after the infarction with the attendant clinical symptoms and elevation in myocardial enzymes or (2) the presence of changes in Q-waves on serial electrocardiograms demonstrated a myocardial infarction had occurred or (3) the patient had an
elevation of myocardial enzymes that were twice as high as normal levels and typical symptoms of a myocardial infarction were present.

Exclusions to enrollment included: women of child bearing potential unless contraception was used; patients with malignancy thought to reduce survival or requiring radiation therapy; severe valvular heart disease likely to require a surgical procedure; psychologic disorder making the patient unsuitable for a clinical trial; participation in another investigational drug trial; clinical ischemia with no corrective procedure prior to the scheduled time of randomization; ischemia or symptomatic hypotension following the test dose of captopril; failure to randomize within 16 days of the myocardial infarction; relative contraindication to the use of an angiotensin converting enzyme inhibitor or its requirement for the management of symptomatic congestive heart failure or systemic hypertension; a serum creatinine level > 221 μmol/liter (2.5 mg/dl); other conditions thought to limit survival; an unwillingness or inability to participate in a long-term trial; and an unstable course following infarction.

The presence of recurrent ischemic discomfort 72 hours after the onset of the index myocardial infarction, a positive exercise test (>2mm ST segment depression and failure to complete the modified exercise protocol), required that cardiac catheterization and coronary arteriography be performed and a clinical decision made regarding the
need for myocardial revascularization. If required, revascularization had to be performed so as to allow patients to be randomized three to 16 days post-infarction. Of the 8938 patients considered eligible by this initial screening process, 2250 (25.2 percent) had no exclusions and consented to participate in the trial. Prior to randomization, all eligible and consenting patients were given a test dose of open-label captopril 6.25 mg orally. If this initial dose was well tolerated and not associated with significant orthostatic or ischemic symptoms, the patient was randomized to receive either captopril or placebo therapy in a double-blind fashion.

The test dose of 6.25 mg (p.o.) of captopril resulted in the exclusion of 3 patients for associated ischemic discomfort and 16 patients for symptomatic hypotension, yielding a study population of 2231. A more detailed presentation of the screening process and the exclusions to enrollment has been published in The American Journal of Cardiology (19), the entire disclosure of which is incorporated herein by reference.

Randomization, Dose Titration, and Follow-up

Randomization to therapy with either placebo or captopril was achieved by computer-generated allocation and was stratified by center. Two additional stratifications, based on age (above and below 70 years) and left ventricular ejection fraction (above and below 20 percent), insured that the subsets
of patients (age above 70 years and/or ejection fraction below 20 percent) who were at highest risk for adverse events would be evenly distributed between the two therapy groups. The initial dose of the blinded medication was 12.5 mg. However, investigators were allowed to administer a 6.25 mg dose to those patients who had a marked, yet asymptomatic reduction in blood pressure with the test dose. The target dose of study medication was 25 mg three times daily by the end of the in-hospital phase and was titered to a maximum of 50 mg three times daily following discharge from the hospital. If the investigator perceived any adverse experience to the medication, a reduction in dose was permitted. Outpatient visits were begun two weeks after randomization, then scheduled at intervals of three months during the first year of follow-up and at intervals of four months during the remainder of the trial. All patients were followed for a minimum of two years.

At each follow-up visit, a physical examination was performed and interim clinical events were ascertained. Symptoms of myocardial ischemia were noted as was the development of signs and symptoms of congestive heart failure. Patients were categorized according to the presence of severe congestive heart failure at any time during the follow-up period. Assessed, in addition, were the occurrence of recurrent myocardial infarction as well as possible adverse effects of study medication. During the last
ten months of follow-up, all surviving patients were to have a repeat radionuclide ventriculogram. The protocol call for temporary (48 hours) suspension of the study medication prior to repeat determination of the ejection fraction; study medication then was resumed and continued for the remainder of the trial. On average, this repeat ejection fraction was obtained 36 months (range, 15 to 57 months) following randomization.

End Points

Observation was continued to the planned completion date of January 31, 1992, by which time the last patient enrolled had finished a minimum follow-up of severe congestive heart failure or the recurrence of a fatal or non-fatal myocardial infarction; and the combination of cardiovascular mortality and morbidity. Two endpoints of severe heart failure (treatment failure) were prospectively defined: 1) patients who developed and remained in overt heart failure despite the administration of diuretics and digitalis and who therefore required angiotensin converting enzyme inhibition therapy. After determining that the patient could not be managed adequately by conventional therapy (diet, diuretics and/or digitalis), the study medication (placebo or

1Patients who required cardiac transplantation were included in all cause mortality and classified with those who experienced cardiovascular death.
captopril) was discontinued in order to initiate therapy with open-label angiotensin converting enzyme inhibitor (for the already approved use for symptomatic heart failure); and, 2) failure of outpatient treatment and consequent hospitalization for the management of congestive heart failure.

The change in radionuclide ventricular ejection fraction was selected as an objective measure that was anticipated to occur infrequently, but when present was deemed to be of major clinical significance. It was determined that a change of 9 percentage points would signify a decrease that was unlikely to be due to chance alone. In addition, observations of repeat radionuclide ventricular ejection fraction period of two years. Several prospectively defined measures of outcome served as end points in the trial: all cause mortality; cardiovascular mortality; mortality combined with a fall in ejection fraction of at least 9 units in survivors; cardiovascular morbidity, defined as the development determinations confirmed that patients with ejection fraction deteriorations greater than or equal to 9% were experiencing an increased risk of death, making this magnitude of deterioration clinically relevant.

Statistical Analysis

The statistical method has been described in detail previously (20). A sample size of 2200 patients was estimated. All analyses were as intention to treat and all P values were two-sided.
Comparability of base-line characteristics of the two treatment groups was ascertained by chi-square tests for categorical variables and standard normal (z) tests for continuous variables. A proportional hazards regression model with time-dependent covariates was used to assess the relative risk of death for patients who experienced heart failure requiring therapy with open-label angiotensin converting enzyme inhibitor or hospitalization. A chi-square test statistic for comparing the occurrence of endpoints across a treatment group was performed and its results are displayed in the text and tables. The analysis of the combined endpoint of the occurrence of either death or survival and a ≥ 9 unit reduction in ejection fraction, which considered the time to death or a change of ≥ 9 units of ejection fraction in survivors, was based on the Gehan statistic (21). Kaplan-Meier estimates were used to assess the differences in the distributions of time from randomization to the clinical event of interest as displayed in the life table figures (1 and 3). The log-rank test statistic was used to analyze the life-table date by therapy assignment for the first four years of follow-up.

Results

The 2231 patients enrolled in the trial were followed for an average of 43 ± 10 months, from the prospectively defined minimum of 24 months to a maximum of 60 months. At the completion of this
follow-up period, the vital status of 6 patients (4 placebo and 2 captopril) had not yet been ascertained. There were no differences in the characteristics of the patients assigned to placebo or of captopril at the time just prior to randomization. Blood pressure increased in both treatment groups from base line to three months, albeit to differing extents, so that both systolic and diastolic pressures of the placebo group were significantly higher than those in the captopril group at three months. This difference was maintained during follow-up (one-year visit for placebo, 125 ± 18/77 ± 10 and for captopril, 119 ± 18/74 ± 10 mmHg; P < 0.001, for both systolic and diastolic pressures). The heart rate for both groups was, on average, 72 beats per minute.

Mortality

From the onset (January 27, 1987) to the termination (January 31, 1992) of the trial, there were 503 deaths, of which 275 of 1116 (24.6 percent) were in the placebo group and 228 of 1115 (20.4 percent) in the captopril group; the reduction in risk for all cause mortality was 19 percent (95 percent confidence interval, 3 to 32 percent; P=0.019) (Figure 1, Table 1).

A repeat ejection fraction was obtained in 1644 of the 1728 surviving patients [96 percent (806/841) of those on placebo and 95 percent (838/887) of those on captopril] and a deterioration of 9 or more units was noted in 15 percent (125/806) of the patients in
the placebo group and in 13 percent (110/838) of the patients in the captopril group (P=0.168). When this measure of progressive left ventricular dysfunction was combined with all cause mortality, this prospectively defined endpoint was realized in 36 percent (400/1116) of patients on placebo and in 30 percent (338/1115) of patients on captopril; the reduction in risk was 15 percent (95 percent confidence interval, 5 to 25 percent; P=0.006) (Table 1).

Table 1. Total Mortality and Survival with Deterioration in Left Ventricular Ejection Fraction According to Treatment Group.

<table>
<thead>
<tr>
<th>Event</th>
<th>Placebo (N=1116)</th>
<th>Captopril (N=1115)</th>
<th>Risk Reduction (95% CI)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Cause Mortality</td>
<td>275 (24.6)</td>
<td>228 (20.4)</td>
<td>19 (3 to 32)</td>
<td>0.019</td>
</tr>
<tr>
<td>Alive and Observed</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Observed Reduction</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LVEF &gt; 9 Units</td>
<td>125 (16)</td>
<td>110 (13)</td>
<td>11 (-13 to 30)</td>
<td>0.303</td>
</tr>
<tr>
<td>Death of Reduction</td>
<td>400 (36)</td>
<td>338 (30)</td>
<td>15 (5 to 25)</td>
<td>0.006</td>
</tr>
</tbody>
</table>

Death or survival with an observed reduction in left ventricular ejection fraction (LVEF) of > 9 units was also compared with a modified Gehan (18) statistic which considers duration between ejection fraction determinations as well as duration of survival. This analysis also demonstrated a significant improvement in this endpoint for patients randomized to captopril (p=0.019).
Of the total mortality, 84 percent (422/503) of the deaths were secondary to cardiovascular events, 234 in the placebo group and 188 in the captopril group; the reduction in risk was 21 percent (95 percent confidence interval, 5 to 35 percent; \( P=0.014 \)) (Table 2). Within this category of cardiovascular death there was a marked reduction in mortality due to cardiac pump failure in the captopril group when compared with the placebo group (58 deaths in the placebo group versus 38 in the captopril group; these 96 deaths included the twelve patients who underwent cardiac transplantation, 7 in the placebo group and 5 in the captopril group); the reduction in risk from cardiac pump failure was 36 percent (95 percent confidence interval, 4 to 58 percent; \( P=0.032 \)). Non-cardiovascular causes accounted for 16 percent of total mortality and were distributed evenly between the two treatment groups (Table 2). Specifically, there were no differences between the placebo and captopril groups in deaths due to neoplasm, including gastrointestinal neoplasm.
Table 2. Causes of Death in the Study Patients*

<table>
<thead>
<tr>
<th>Cause of Death</th>
<th>Placebo no. of deaths</th>
<th>Captopril no. of deaths</th>
<th>Risk Reduction (95% CI)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atherosclerotic heart disease</td>
<td>222</td>
<td>174</td>
<td>23 (6-37)</td>
<td>0.009</td>
</tr>
<tr>
<td>Progressive heart failure+</td>
<td>58</td>
<td>38</td>
<td>36 (4-58)</td>
<td>0.032</td>
</tr>
<tr>
<td>Sudden, with preceding symptoms</td>
<td>50</td>
<td>43</td>
<td>--</td>
<td>NS</td>
</tr>
<tr>
<td>Sudden, unexpected</td>
<td>75</td>
<td>62</td>
<td>--</td>
<td>NS</td>
</tr>
<tr>
<td>Acute myocardial infarction</td>
<td>25</td>
<td>24</td>
<td>--</td>
<td>NS</td>
</tr>
<tr>
<td>Cardiac procedure</td>
<td>9</td>
<td>5</td>
<td>--</td>
<td>NS</td>
</tr>
<tr>
<td>Other cardiac</td>
<td>5</td>
<td>2</td>
<td>--</td>
<td>NS</td>
</tr>
<tr>
<td>Vascular</td>
<td>12</td>
<td>14</td>
<td>--</td>
<td>NS</td>
</tr>
<tr>
<td>Noncardiovascular</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cancer</td>
<td>20</td>
<td>14</td>
<td>--</td>
<td>NS</td>
</tr>
<tr>
<td>Infection or gastrointestinal bleeding</td>
<td>18</td>
<td>16</td>
<td>--</td>
<td>NS</td>
</tr>
<tr>
<td>Traumatic or unknown</td>
<td>3</td>
<td>10</td>
<td>--</td>
<td>NS</td>
</tr>
<tr>
<td>All</td>
<td>275</td>
<td>228</td>
<td>19 (3-32)</td>
<td>0.019</td>
</tr>
</tbody>
</table>

* CI denotes confidence interval, and NS not significant.
+ Death was attributed to progressive heart failure if it occurred during a hospitalization for management of heart failure or if it was preceded by a recent deterioration in clinical status attributed to heart failure.

Cardiovascular Morbidity

Figure 2 is a bar graph depicting cardiovascular morbidity and mortality in the captopril and placebo groups. The total bar represents the number of patients experiencing the event in each group and the symbol designates a significant reduction in the event
for captopril-treated patients. The lower solid portion of each bar represents the number of patients who manifested the specific cardiovascular event and subsequently died; the symbol next to the solid bar designates a significant reduction in the mortality of the captopril-treated patients experiencing the event (*P < 0.05; + P < 0.005).

The incidence of failure of treatment of congestive heart failure with digitalis and diuretics requiring open-label therapy with angiotensin converting enzyme inhibitor increased progressively during the average 43 months of follow-up: 13 percent (297/2231) of the enrolled population manifested this degree of heart failure (Figure 2). Irrespective of therapy assignment, this need for the use of open-label angiotensin converting enzyme inhibitor was associated with an increased risk of death: 37 percent (110/297) of those patients who exhibited this degree of heart failure went on to die, while 20 percent (393/1934) of those patients who did not require an angiotensin converting enzyme inhibitor died during the period of observation (relative risk = 4.5; 95 percent confidence interval, 3.6 to 5.6; P<0.001). However, patients randomized to receive captopril were significantly less likely to exhibit this form of treatment failure when compared with those on placebo [179 of 1116 (16.0 percent) on placebo versus 118 of 1115 (10.6 percent) on captopril]; the reduction in risk for requiring open-label angiotensin converting enzyme inhibition
was 37 percent (95 percent confidence interval, 20 to 50 percent; P<0.001) (Figure 2). The group randomized to captopril also exhibited a considerable reduction in the number of patients who died subsequent to going on open-label therapy with an angiotensin converting enzyme inhibitor (71 on placebo versus 39 on captopril; the reduction in risk was 47 percent; 95 percent confidence interval, 21 to 64 percent; P=0.002) (Figure 2).

Treatment failure resulting in the need for hospitalization for the management of congestive heart failure was an even worse prognostic sign: 15 percent (346/2231) of the enrolled population manifested this degree of heart failure. Irrespective of therapy assignment, the requirement of hospitalization for the management of congestive heart failure was associated with a markedly increased risk of death: 47 percent (164/346) of those patients who exhibited this degree of heart failure went on to die while 18 percent (339/1885) of those patients who were not hospitalized for heart failure died (relative risk = 6.4; 95 percent confidence interval, 5.3 to 7.8; P<0.001). Randomization to captopril therapy reduced the number of patients who required hospitalization for congestive heart failure (placebo: 17 percent, 192 of 1116 versus captopril: 14 percent, 154 of 1115; the reduction in risk for hospitalization for heart failure was 22 percent; 95 percent confidence interval, 4 to 37 percent; P=0.019). The captopril group also exhibited a substantial reduction in the
number of patients who were hospitalized for congestive heart failure and who subsequently died (101 on placebo versus 64 on captopril; the reduction in risk was 38 percent; 95 percent confidence interval, 15 to 54 percent; \( P=0.003 \)) (Figure 2).

There were 303 clinical, recurrent myocardial infarctions, 170 of which occurred in the placebo group and 133 in the captopril group; the reduction in risk was 25 percent (95 percent confidence interval, 5 to 40 percent; \( P=0.015 \)) (Figure 2). The number of deaths following a recurrent myocardial infarction tended to be lower in the captopril group when compared with placebo (placebo, 80 and captopril, 56); the reduction in risk was 32 percent (95 percent confidence interval, 4 to 51 percent; \( P=0.029 \)).

Figures 3–8 show life table graphs which illustrate the beneficial effect of captopril therapy in reducing the incidence of the major adverse cardiovascular events. Figure 3 shows the benefit of captopril therapy for decreasing cardiovascular mortality; Figure 4 shows the benefit of captopril therapy for reducing the incidence of congestive heart failure requiring ACE inhibition; Figure 5 shows the benefit of captopril therapy for decreasing the incidence of hospitalization due to heart failure; Figure 6 shows the benefit of captopril therapy for reducing recurrent myocardial infarction; Figure 7 shows the benefit of captopril therapy for reducing both cardiovascular mortality and recurrent MI; and Figure 8 shows the benefit of captopril therapy for
reducing both cardiovascular mortality and morbidity (severe heart failure requiring either ACE inhibitor therapy, hospitalization, or development of recurrent myocardial infarction). (For all combined analyses, only the time to first event was utilized).

The effect on all cause mortality and cardiovascular mortality and morbidity of major, prospectively specified, pre-randomization characteristics known to influence survival following myocardial infarction was as anticipated; that is, irrespective of treatment assignment, advanced age, history of prior myocardial infarction, lower left ventricular ejection fraction, and higher Killip Classification were associated with a greater incidence of adverse events. When these subgroups were analyzed, captopril therapy showed a consistent benefit, although to varying degrees, in reducing all cause mortality and cardiovascular mortality and morbidity (Table 3). Of particular note was the efficacy of captopril in Killip class I patients, i.e., those who did manifest even transient pulmonary congestion at the time of their acute myocardial infarction. Captopril also was efficacious in patients who were receiving aspirin and/or beta-blocking agents at the time of randomization, illustrating its additive value to an already proven therapy for the management of patients following a myocardial infarction. The directional benefit of captopril was uniform, for in no instance was its effect on risk reduction discordant within subgroups.
Table 3. Effect of Captopril on Major Clinical Endpoints in Various Subgroups Known to Have Important Influence on Survival Following Myocardial Infarction.

<table>
<thead>
<tr>
<th>VARIABLE</th>
<th>PLACEBO</th>
<th>CAPTOPRIL</th>
<th>RISK REDUCTION (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>events/number (percent)</td>
<td>events/number (percent)</td>
<td>percent</td>
</tr>
<tr>
<td>Death (All Cause)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years):</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤55</td>
<td>54/365 (14.8)</td>
<td>52/375 (13.9)</td>
<td>8 (-34 to 37)</td>
</tr>
<tr>
<td>56-64</td>
<td>77/352 (21.9)</td>
<td>69/356 (19.4)</td>
<td>13 (-21 to 37)</td>
</tr>
<tr>
<td>&gt; 64</td>
<td>144/399 (36.1)</td>
<td>107/384 (27.9)</td>
<td>25 (4 to 42)</td>
</tr>
<tr>
<td>Sex: male</td>
<td>234/912 (25.7)</td>
<td>191/929 (20.6)</td>
<td>22 (6 to 36)</td>
</tr>
<tr>
<td>female</td>
<td>41/204 (20.1)</td>
<td>37/186 (19.9)</td>
<td>2 (-53 to 37)</td>
</tr>
<tr>
<td>Prior Myocardial Infarction:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>144/721 (20.0)</td>
<td>115/718 (16.0)</td>
<td>22 (0 to 39)</td>
</tr>
<tr>
<td>Yes</td>
<td>131/395 (33.2)</td>
<td>113/397 (28.5)</td>
<td>16 (-8 to 35)</td>
</tr>
<tr>
<td>EF (percent):</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt; 32</td>
<td>77/517 (14.9)</td>
<td>75/531 (14.1)</td>
<td>6 (-29 to 32)</td>
</tr>
<tr>
<td>≤32</td>
<td>198/599 (33.1)</td>
<td>153/584 (26.2)</td>
<td>24 (6 to 38)</td>
</tr>
<tr>
<td>Killip Class:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>140/672 (20.8)</td>
<td>109/676 (16.1)</td>
<td>25 (4 to 42)</td>
</tr>
<tr>
<td>II or higher</td>
<td>135/444 (30.4)</td>
<td>119/439 (27.1)</td>
<td>11 (-14 to 31)</td>
</tr>
<tr>
<td>Myocardial Infarction Classification by ECG:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anterior Q</td>
<td>117/605 (19.3)</td>
<td>112/624 (17.9)</td>
<td>9 (-19 to 29)</td>
</tr>
<tr>
<td>Inferior Q</td>
<td>41/193 (21.2)</td>
<td>36/201 (17.9)</td>
<td>16 (-32 to 46)</td>
</tr>
<tr>
<td>Both</td>
<td>48/135 (35.6)</td>
<td>30/126 (23.8)</td>
<td>38 (2 to 60)</td>
</tr>
<tr>
<td>Non Q</td>
<td>34/110 (30.9)</td>
<td>22/106 (20.8)</td>
<td>36 (-10 to 62)</td>
</tr>
<tr>
<td>Other</td>
<td>35/73 (47.9)</td>
<td>28/58 (48.3)</td>
<td>-2 (-69 to 38)</td>
</tr>
<tr>
<td>Thrombolytic Therapy:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>58/355 (16.3)</td>
<td>48/376 (12.8)</td>
<td>22 (-14 to 47)</td>
</tr>
<tr>
<td>No</td>
<td>217/761 (28.5)</td>
<td>180/739 (24.4)</td>
<td>17 (-1 to 32)</td>
</tr>
<tr>
<td>Beta Blocker:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>76/398 (19.1)</td>
<td>52/391 (13.3)</td>
<td>33 (4 to 53)</td>
</tr>
<tr>
<td>No</td>
<td>199/718 (27.7)</td>
<td>176/724 (24.3)</td>
<td>14 (-5 to 30)</td>
</tr>
<tr>
<td>Aspirin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>140/653 (21.4)</td>
<td>109/657 (16.6)</td>
<td>24 (2 to 41)</td>
</tr>
<tr>
<td>No</td>
<td>135/463 (29.2)</td>
<td>119/458 (26.0)</td>
<td>14 (-10 to 33)</td>
</tr>
<tr>
<td>TOTAL</td>
<td>275/1116 (24.6)</td>
<td>228/1115 (20.4)</td>
<td>19 (3 to 32)</td>
</tr>
</tbody>
</table>
### Table 3 continued.

#### CV Death or Morbidity

<table>
<thead>
<tr>
<th>VARIABLE</th>
<th>PLACEBO</th>
<th>CAPTOPRIL</th>
<th>RISK REDUCTION</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>events/number (percent)</td>
<td>events/number (percent)</td>
<td>(95% CI) percent</td>
</tr>
<tr>
<td>Age (years):</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 55</td>
<td>104/365 (28.5)</td>
<td>97/375 (25.9)</td>
<td>10 (-18 to 32)</td>
</tr>
<tr>
<td>56-64</td>
<td>152/352 (43.2)</td>
<td>112/356 (31.5)</td>
<td>34 (16 to 45)</td>
</tr>
<tr>
<td>&gt; 64</td>
<td>192/399 (48.1)</td>
<td>150/384 (39.1)</td>
<td>23 (5 to 38)</td>
</tr>
<tr>
<td>Sex: male</td>
<td>367/912 (40.2)</td>
<td>288/929 (31.0)</td>
<td>28 (16 to 38)</td>
</tr>
<tr>
<td>female</td>
<td>81/204 (39.7)</td>
<td>71/166 (38.2)</td>
<td>4 (-32 to 30)</td>
</tr>
<tr>
<td>Prior Myocardial Infarction:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>228/721 (31.6)</td>
<td>186/718 (25.9)</td>
<td>21 (4 to 35)</td>
</tr>
<tr>
<td>Yes</td>
<td>220/395 (55.7)</td>
<td>173/397 (43.6)</td>
<td>29 (13 to 42)</td>
</tr>
<tr>
<td>EF (percent):</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt; 32</td>
<td>155/517 (30.0)</td>
<td>124/531 (23.4)</td>
<td>27 (7 to 42)</td>
</tr>
<tr>
<td>≤ 32</td>
<td>293/599 (48.9)</td>
<td>235/584 (40.2)</td>
<td>22 (7 to 34)</td>
</tr>
<tr>
<td>Killip Class:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>225/672 (33.5)</td>
<td>179/676 (26.5)</td>
<td>25 (8 to 38)</td>
</tr>
<tr>
<td>II or higher</td>
<td>223/444 (50.2)</td>
<td>180/439 (41.0)</td>
<td>23 (7 to 37)</td>
</tr>
<tr>
<td>Myocardial Infarction Classification by ECG:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anterior Q</td>
<td>198/605 (32.7)</td>
<td>177/624 (28.4)</td>
<td>16 (-3 to 31)</td>
</tr>
<tr>
<td>Inferior Q</td>
<td>76/193 (39.4)</td>
<td>61/201 (30.3)</td>
<td>28 (-1 to 49)</td>
</tr>
<tr>
<td>Both</td>
<td>75/135 (55.6)</td>
<td>50/126 (39.7)</td>
<td>35 (7 to 55)</td>
</tr>
<tr>
<td>Non Q</td>
<td>51/110 (46.4)</td>
<td>38/106 (35.8)</td>
<td>31 (5 to 55)</td>
</tr>
<tr>
<td>Other</td>
<td>48/73 (65.8)</td>
<td>33/58 (56.9)</td>
<td>20 (-25 to 49)</td>
</tr>
<tr>
<td>Thrombolytic Therapy:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>117/355 (33.0)</td>
<td>99/376 (26.3)</td>
<td>23 (-1 to 41)</td>
</tr>
<tr>
<td>No</td>
<td>331/761 (43.5)</td>
<td>260/739 (35.2)</td>
<td>24 (11 to 36)</td>
</tr>
<tr>
<td>Beta Blocker:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>132/398 (33.2)</td>
<td>103/391 (26.3)</td>
<td>26 (4 to 43)</td>
</tr>
<tr>
<td>No</td>
<td>316/718 (44.0)</td>
<td>256/724 (35.4)</td>
<td>23 (10 to 35)</td>
</tr>
<tr>
<td>Aspirin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>239/653 (36.6)</td>
<td>203/657 (30.9)</td>
<td>20 (3 to 33)</td>
</tr>
<tr>
<td>No</td>
<td>209/463 (45.1)</td>
<td>156/458 (34.1)</td>
<td>29 (13 to 43)</td>
</tr>
</tbody>
</table>

**TOTAL** | 448/1116 (40.1) | 359/1115 (32.2) | 24 (13 to 34) |
CV Death or Morbidity designates either a death classified as having a cardiovascular origin or the development of congestive heart failure requiring the use of open-label angiotensin converting enzyme inhibitor for management of congestive heart failure, the development of heart failure requiring a hospital admission for management, or a recurrent myocardial infarction. With this analysis, any patient can only experience one of these major fatal or non-fatal cardiovascular events. The percentage risk reduction and 95% confidence interval (CI) are indicated in brackets.

EF indicates radionuclide left ventricular fraction at base-line.
MI indicates myocardial infarction.
ECG indicates electrocardiogram.

Adherence and Adverse Study Drug Experience

The number of patients taking their assigned study medication at one-year was similar for the placebo (808/985, 82 percent) and captopril (787/1001, 79 percent) groups (P=NS). At the last study visit, 73 percent (612/841) of the patients in the placebo group and 70 percent (619/887) of the patients in the captopril group were still on study drug (P=NS). Of those taking their assigned study medication at the last visit, 90 percent (549/612) of placebo and 79 percent (486/619) of captopril patients achieved the target dose of 150 mg per day.

Captopril-treated patients registered significantly more (Z > 1.96, uncorrected; excess over placebo) complaints of dizziness (5.5 percent); taste alteration (2.5 percent); diarrhea (2.1 percent); and cough (6.2 percent). The number of patients who
discontinued study medication at the time of these adverse events in the placebo and captopril groups, respectively, was: 25 and 32 for dizziness (P = NS); 5 and 9 for taste alteration (P = NS); 9 and 27 for cough (P = 0.003); and none for diarrhea. A minor, but statistically significant difference in the serum creatinine level was detected between the treatment groups during the follow-up period (two-year values for placebo and captopril, respectively: 106 versus 110 μmol/liter, or 1.20 versus 1.24 mg/dl; P = 0.014).

DISCUSSION

The randomization window of 3 to 16 days was chosen to allow the treating physician time to formulate an individualized plan for the management of coronary artery disease. Indeed, of the total study population, 55 percent had a catheterization and 26 percent had a revascularization procedure (9 percent had coronary artery bypass surgery and 17 percent had percutaneous transluminal coronary angioplasty) performed following the infarction but prior to enrollment. Although this randomization period precluded the opportunity for captopril to influence the early (< 72 hours) changes in left ventricular topography that may occur following myocardial infarction (22), the long-term efficacy of captopril therapy in reducing adverse clinical events did not appear to be influenced by the differences in the time to initiation of therapy (Table 3).
The selection of patients with objective evidence of left ventricular dysfunction (ejection fraction < 40 percent) was based on the finding in previous clinical studies (17,18) that captopril attenuated ventricular dilatation in this patient population. The exclusion from this trial of patients with symptomatic heart failure who required vasodilators was based on the demonstrated efficacy of this therapy for the treatment of heart failure (23,24,25). In the present study the efficacy of captopril therapy in reducing death and major adverse cardiovascular events appeared to increase during follow-up (Figures 1 and 3-8), underscoring the value of this agent as preventive therapy in patients with left ventricular dysfunction but without overt heart failure following a myocardial infarction.

The present study demonstrates that the long-term administration of captopril to survivors of a myocardial infarction, a high risk population, resulted in a reduction not only in the manifestation of heart failure, but also in the number of subsequent fatal events.

Although not wishing to be bound by any particular theory, the favorable effects of captopril therapy may be explained by its attenuation of ventricular remodeling and/or by its direct inhibition of the proposed deleterious effects of neurohumoral activation (26). These purported mechanisms by which captopril might exert its beneficial effects are not mutually exclusive. Indeed, the combination of
ventricular enlargement and elevated plasma levels of neurohormones at base line was associated with a greater risk of death than that for the presence of these adverse prognostic indicators alone (27). These same actions of captopril on ventricular remodeling and neurohumoral profile may also be operative in reducing the incidence of recurrent myocardial infarction.

The foregoing description of the invention and the example demonstrating the application of the invention are but illustrative. Other variations and equivalents will be apparent to those of ordinary skill in the art. Therefore, the present invention is to be considered limited only by the appended claims.

REFERENCES


15. The Multicenter European Research Trial with Cilazapril After Angioplasty to Prevent


20. Moye LA, Pfeffer MA, Braunwald E, for the SAVE Investigators. Rationale, design and baseline characteristics of the survival and ventricular enlargement trial. Am J Cardiol 1991; 68:70D-79D.


26. Packer M, Lee WH, Kessler PD, Gottlieb SS, Bernstein JL, Kukin ML. Role of neurohormonal

What we claim is:

CLAIMS

1. Use of a renin-angiotensin system inhibitor for the manufacture of a medicament for use in a method of treating a human survivor of a heart attack by long-term administration of said medicament.

2. Use of a renin-angiotensin system inhibitor for the manufacture of a medicament for use in a method of treating a human survivor of a heart attack, wherein the human survivor is free of indications for renin-angiotensin system inhibitor treatment.

3. A use as claimed in claim 2, wherein the method comprises long-term administration of the medicament.

4. A use as claimed in any one of claims 1–3, wherein the renin-angiotensin system inhibitor is an angiotensin converting enzyme inhibitor.

5. A use as claimed in any one of claims 1–3, wherein the renin-angiotensin system inhibitor is a renin inhibitor.

6. A use as claimed in any one of claims 1–3, wherein the renin-angiotensin system inhibitor is an
angiotensin II inhibitor or antagonist.

7. A use as claimed in claim 4, wherein the angiotensin converting enzyme inhibitor is an acylmercapt proline, a mercaptoalkanoyl proline, a carboxyalkyl dipeptide, a carboxyalkyl dipeptide mimic or a phosphinyalkanloyl proline.

8. A use as claimed in claim 5, wherein the renin inhibitor is a peptide.

9. A use as claimed in any one of the preceding claims, wherein the method further comprises administering a further compound or composition to the human survivor, wherein the further compound or composition is therapeutically active in the treatment of a heart attack consequence and is not a renin-angiotensin system inhibitor.

10. A use as claimed in claim 9, wherein the further compound or composition comprises a beta-adrenergic blocking agent, an anticoagulant, a thrombolytic agent, or aspirin.

11. A use as claimed in claim 8 or 9, wherein the further compound or composition is used in the preparation of the medicament.

12. A use as claimed in any of the preceding claims, wherein the method comprises administering the medicament for a period of at least six months.
13. A use as claimed in claim 11, wherein the medicament is administered for a period of at least two years.

14. A use as claimed in any of the preceding claims, wherein the method comprises administering the medicament to the human survivor within sixteen days of a heart attack.

15. A use as claimed in any one of the preceding claims, wherein the method comprises administering the medicament to the human survivor in a period commencing three days after a heart attack.

16. A use as claimed in any of claims 1-4, 7 and 9-15, wherein the renin-angiotensin system inhibitor is an angiotensin converting enzyme inhibitor and the method comprises administering the medicament to provide a lower dose of the inhibitor, at the start of the treatment, and a higher dose thereof, during a subsequent stage of the treatment.

17. A use as claimed in any of the preceding claims, wherein the method comprises administering the medicament three times per day.

18. A use as claimed in any of the preceding claims, wherein the renin-angiotensin system inhibitor is captopril.
19. A use as claimed in claim 17, wherein the method comprises administering captopril at a dose of less than 20mg per day, at the commencement of treatment, and at a dose of up to 150mg per day during a subsequent stage of the treatment.

20. A use as claimed in claim 18, wherein the method comprises administering captopril at an initial dose of about 6.25mg, three times per day, a first intermediate dose of about 12.5mg, three times per day, a second intermediate dose of about 25mg, three times per day, and a final dose of a tolerable amount of up to 50mg, three times per day.

21. A use as claimed in any of the preceding claims, wherein the medicament is administered to achieve a maximum tolerable dose of the renin-angiotensin system inhibitor.

22. A use as claimed in any of the preceding claims, wherein the method comprises treating a human survivor of myocardial infarction.

23. A use as claimed in any of the preceding claims, wherein the method comprises treating a human survivor with depressed left ventricular ejection fraction but without overt heart failure.

24. A use as claimed in any of the preceding claims, wherein the method comprises treating a
human survivor with a left ventricular ejection fraction of less than or equal to 40% after a heart attack.

25. A use as claimed in any of the preceding claims, further comprising mixing the renin-angiotensin system inhibitor with a suitable pharmaceutical excipient or excipients.

26. A use as claimed in any of the preceding claims, wherein the medicament is suitable for administration by an oral, rectal, topical, nasal, transcutaneous or parenteral route.

27. A use as claimed in any of the preceding claims, wherein the method reduces the chances of adverse health consequences following a heart attack.

28. A use as claimed in any of the preceding claims, wherein the human survivor exhibits asymptomatic left ventricular dysfunction.

29. A composition comprising a renin-angiotensin system inhibitor in admixture with a further active compound or composition, wherein the further compound or composition is effective in treating a heart attack consequence and is not a renin-angiotensin system inhibitor.
30. A composition as claimed in claim 29, wherein said further compound or composition is a beta-adrenergic blocking agent, an anticoagulant, a thrombolytic agent, or aspirin.
FIG. 1

Placebo 1116  987  915  609  262
Captopril 1115 1000  938  614  268

Risk Reduction = 19%
P = 0.019
FIG. 2
FIG. 3

CARdiovascular Mortality

Event Rate

0.3
0.2
0.1
0
Placebo
Captopril

Risk Reduction = 21%
P = 0.014

Years

1 2 3 4
FIG. 4

CHF REQUIRING ACE INHIBITION

Event Rate

Placebo
Captopril
Risk Reduction = 37%
P < 0.001

Years

0 0.1 0.2 0.3

1 2 3 4
HOSPITALIZATION FOR HEART FAILURE

Event Rate

Risk Reduction = 22%
P = 0.019

FIG. 5
RECURRENT MYOCARDIAL INFARCTION

Event Rate

Placebo
Captopril

Risk Reduction = 25 %
P = 0.015

Years

FIG. 6
CARIOVASCULAR MORTALITY OR RECURRENT MI

Event Rate

Placebo
Captopril

Risk Reduction = 22%
P = 0.003

Years

FIG. 7
FIG. 8

CARDIOVASCULAR MORTALITY/MORBIDITY

Event Rate

Risk Reduction = 24%
P < 0.001

Placebo

Captopril

Years

0 1 2 3 4